SSE Ticker: 600664

Harbin Pharmaceutical Group Co., Ltd.

哈药股份

Authorized Representative: 张镇平

Board: Main A

Industry Classification: Manufacturing

Xu Haiying, general manager of Harbin Pharmaceutical Co., Ltd., resigned

Post date May 16, 2022 — 17:30 Post Lock

Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned from the company's director, member of the strategy and decision-making committee of the board of directors, and general manager

Post date May 16, 2022 — 17:27 Post Lock

Harbin Pharmaceutical Co., Ltd.: Xu Haiying resigned as director of the company, member of the strategy and decision-making committee of the board of directors, and general manager_Oriental Fortune Net

Post date May 16, 2022 — 17:26 Post Lock

Xu Haiying, General Manager of Harbin Pharmaceutical Co., Ltd. (600664.SH), resigns

Post date May 16, 2022 — 17:25 Post Lock

Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years, Sales of Many Major Categories Decline

Post date May 13, 2022 — 11:03 Post Lock

Zhendong Pharmaceutical has received a letter of inquiry about the annual report for three consecutive years. The sale of its subsidiary has taken out Fangyuan Capital. Zhendong Pharmaceutical, Fangyuan Capital, Shenzhen Stock Exchange_Sina Technology_Sina.com

Post date May 13, 2022 — 08:55 Post Lock

Zhendong Pharmaceutical Receives Annual Report Inquiry Letters for Three Consecutive Years

Post date May 13, 2022 — 08:50 Post Lock

[Assignment] Renmin Tongtai (600829): 2021 Annual Results and Cash Dividend Presentation Session- CFi.CN Zhongcai Network

Post date May 12, 2022 — 22:57 Post Lock

[Express] 7 stocks faced selling pressure on Thursday and 770 million shares were lifted-CFi.CN Zhongcai Network

Post date May 11, 2022 — 18:55 Post Lock

Shanghai and Shenzhen stock market trading tips (May 11)

Post date May 11, 2022 — 09:40 Post Lock

Renmin Tongtai (600829): Appointment of senior management personnel of the company CFi.CN Zhongcai Network

Post date April 28, 2022 — 17:44 Post Lock

Harbin Pharmaceutical (600664.SH): Cefradine Capsule Passes Consistency Evaluation of Generic Drugs

Post date April 27, 2022 — 23:21 Post Lock

Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21% – yqqlm

Post date April 27, 2022 — 23:16 Post Lock

Harbin Pharmaceutical Co., Ltd. (600664.SH) reported a net profit of 100 million yuan in the first quarter, a year-on-year increase of 21.21%_Stock Information_Market Gold Online

Post date April 27, 2022 — 22:37 Post Lock

Harbin Pharmaceutical (600664.SH) net profit in the first quarter was 100 million yuan, a year-on-year increase of 21.21% – yqqlm

Post date April 27, 2022 — 22:15 Post Lock

Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs_Oriental Fortune Network

Post date April 27, 2022 — 21:23 Post Lock

Harbin Pharmaceutical Co., Ltd.: Cefradine Capsule Passes Consistency Evaluation of Generic Drugs

Post date April 27, 2022 — 21:21 Post Lock

Harbin Pharmaceutical Co., Ltd. turned losses through demolition? Government subsidy contributed 370 million profits in 5 years, and the annual salary of the general manager increased by 700,000 per year

Post date April 24, 2022 — 22:44 Post Lock

2021 Earnings Season Pien Tze Huang: The cost of drugs for liver diseases, the mainstay of revenue, has grown, and the gross profit has declined slightly. The core strategy is adjusted by changing the chairman twice a year.

Post date April 18, 2022 — 13:42 Post Lock

Pien Tze Huang: The cost of drugs for liver disease, the mainstay of revenue, has grown, and the gross profit has dropped slightly, and the core strategy of changing the chairman twice a year has been adjusted.

Post date April 18, 2022 — 13:25 Post Lock

Want to see more data? Registered subscribers can see all the data.